ABBOTT LABORATORIES reported revenue of $12.59B for the period ended 2026-06-30, +13.0% year on year. Net income was $0.93B, a 7.4% net margin on a 57.7% gross margin. The largest revenue line is International at 59% of the total.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $12.59B | +13.0% |
| Gross profit | $7.27B | — |
| Operating income | $1.69B | — |
| Net income | $0.93B | -47.8% |
| Gross margin | 57.7% | Net margin 7.4% |
| Revenue Q/Q | +12.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| International | $7.38B | 58.6% |
| U.S | $5.22B | 41.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $5.33B | 42.3% |
| R&D | $0.89B | 7.1% |
| SG&A | $4.03B | 32.0% |
| Tax & other | $0.77B | 6.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ABBV ・ ACN ・ ADBE ・ AMD ・ AES ・ AFL ・ A ・ APD ・ ABNB ・ AKAM ・ ALB ・ ARE
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies